EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein

Cellular and Molecular Immunology

Volumn 6, Issue 4, 2009, Pages 269-276

  Chen, Yun ^a   Sun, Hua ^b   Liu, Genyan ^a   Wang, Bing ^a   Wang, Fang ^a   Sun, Beicheng ^a   Yao, Kun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cytotoxicity; Dendritic cell; Epstein Barr virus; Latent membrane 2

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; LATENT MEMBRANE PROTEIN 2A; UNCLASSIFIED DRUG; VIRUS PROTEIN; LATENT MEMBRANE PROTEIN 2; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; MALE; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY; VIRUS CARRIER; VIRUS INFECTION; CELL STIMULATION; CELL STRAIN K 562; CYTOKINE RELEASE; DRUG CYTOTOXICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERIPHERAL BLOOD MONONUCLEAR CELL; CYTOTOXICITY; EPSTEIN BARR VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOGENICITY; PATHOLOGY; SECRETION;

HUMAN HERPESVIRUS 4;

ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON-GAMMA; K562 CELLS; LYMPHOCYTE ACTIVATION; TH1 CELLS; VIRAL MATRIX PROTEINS;

EID: 69949136027     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.36     Document Type: Article

References (42)

1. Hislop AD, Taylor GS, Sauce D, Rickinson, AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. (Pubitemid 46697918)
2. Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90:3245-3287.
3. Finn OJ. Cancer Immunology. N Engl J Med. 2008;358:2704-2715.
4. Armstrong AC, Hawkins RE. Vaccines in oncology: background and clinical potential. Br J Radiol. 2001;74:991-1002.
5. King J, Waxman J, Stauss H. Advances in tumor immunotherapy. QJM. 2008;101:675-683.
6. Sensi M, Anichini A. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin Cancer Res. 2006;12:5023-5032. (Pubitemid 44453327)
7. Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol. 2005;175:1373-1381. (Pubitemid 41023036)
8. Mailliard RB, Dallal RM, Son Yi, Lotze MT. Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen. Immunol Invest. 2000;29:177-185.
9. Wallet MA, Sen P, Tisch R. Immunoregulation of Dendritic Cells. Clin Med Res. 2005;3:166-175.
10. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004;104:2235-2246. (Pubitemid 39331818)
11. Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res. 2004;10:6347S-6352S. (Pubitemid 39287490)
12. Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 2001;61:6445-6450.
13. Gatza E, Okada CY. Tumor cell Lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol. 2002;169:5227-5235. (Pubitemid 35217194)
14. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 2001;61:2618-2624. (Pubitemid 32685847)
15. + T lymphocyte responses. Blood. 2000;96:1857-1864.
16. Straathof KC, Leen AM, Buza EL, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005;175:4137-4147.
17. Cohen JI. Epstein-barr virus infection. N Engl J Med. 2000;343:481-492.
18. Thompson MP, Kurzrock R. Epstein-barr virus and cancer. Clin Cancer Res. 2004;10:803-821.
19. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol. 2000;53:248-254. (Pubitemid 30766047)
20. Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol. 2000;53:238-247. (Pubitemid 30766046)
21. Delecluse HJ, Hammerschmidt W. The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol Pathol. 2000;53:270-279. (Pubitemid 30766050)
22. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol. 1997;158:3325-3334.
23. Bollard CM, Straathof KC, Huls MH, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004;27:317-327.
24. Comoli P, Palma RD, Siena S, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Onc. 2004;15:113-117.
25. Chen Y, Yao K, Wang B, Jian Qing, Genyan Liu. Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A). Cell Mol Immunol. 2008;5:365-372.
26. Lee SP, Chan ATC, Cheung ST, et al. CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor Cells. J Immunol. 2000;165:573-582.
27. + Hodgkin's disease. J Exp Med. 2004;200:1623-1633.
28. Straathof KCM, Bollard CM, Popat U, et al.Treatment of nasopharyngeal carcinoma with Epstein-Barr virus - specific T lymphocytes. Blood. 2005;105:1898-1904. (Pubitemid 40731770)
29. Lin X, Gudgeon NH, Hui EP, et al. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother. 2008;57:963-975.
30. + T lymphocytes directly enhances the immune response to viral and cellular antigens. Proc Natl Acad Sci U S A. 2005;102:3794-3799.
31. + T cell-mediated cutaneous immune responses by restricting effector T cell development through a Fas ligand-dependent mechanism. J Immunol. 2004;172:2286-2295.
32. +-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol. 2004;78:768-778.
33. Norbury CC, Sigal LJ. Cross priming or direct priming: is that really the question? Curr Opin Immunol. 2003;15(1):82-88.
34. + T lymphocytes by immune-stimulating complexes in vivo. Int. Immunol. 2003;15:711-720.
35. Gilboa E, Nair SK, Kim Lyerly H. Immunotherapy of cancer with dendritic cell-based vaccines. Cancer Immunol Immunother. 1998;46:82-87. (Pubitemid 28177482)
36. + T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer. 2002;99:93-99.
37. + responses to Epstein-Barr virus antigens. Blood. 2000;95:241-248.
38. Prete D. The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int Rev Immunol. 1998;16:427-455.
39. + T-helper 1 responses. J Virol. 2001;75:8649-8659.
40. Zhang Y, Wakita Daiko, Chamoto Kenji, et al. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol. 2007;19:151-161. (Pubitemid 46179010)
41. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275-306. (Pubitemid 40563171)
42. Sun H, Yao K, Chen Y, Zhou F. Induction of T-cell immunity against Epstein-Barr virus-associated tumors by means of adenovirally transduced dendritic cells. Chin Med J (Engl). 2004;117:1558-1563. (Pubitemid 39530239)